Contengono acidi grassi efficaci contro un batterio responsabile di molte forme di acne. Le alghe marine e i salmoni hanno in comune alcuni acidi grassi che sembrano essere efficaci contro un batterio responsabile di molte forme di acne e altri disturbi della pelle. Lo sostengono gli scienziati della University of Stirling, Scozia, con una ricerca pubblicata su Marine Drugs che Giovanni D’Agata, presidente dello “Sportello dei Diritti”, associazione che si occupa anche di tutela della salute e quindi di divulgare i più recenti e importanti studi in materia, ritiene opportuno portare all’attenzione del pubblico giacché l’acne costituisce un problema serio che riguarda milioni di giovani e comporta anche non pochi riflessi psicologici nei casi più acuti. Gli autori hanno studiato le proprietà di alcune alghe marine brune, accumulate attraverso la catena del cibo in pesci come i salmoni. Contengono rispettivamente l’acido Epa omega 3 e l’acido Dgla omega 6, entrambi con proprietà antinfiammatorie, in particolare contro il batterio Propionibacterum acnes. “Gli acidi grassi possono inibire o eliminare i batteri, sono presenti naturalmente sulla pelle ma si possono anche implementare”, si legge nello studio,”si possono assumere mangiando alghe e salmone, oppure spalmando sul viso creme che li contengano”, concludono gli studiosi. Ora stanno sviluppando farmaci topici contenenti questi composti antibatterici contro l’acne e altre patologie della pelle.
Posts contrassegnato dai tag ‘health’
Pubblicato da fidest su venerdì, 6 dicembre 2013
Pubblicato da fidest su martedì, 1 ottobre 2013
Toronto Thursday, October 10, 2013 Health Sciences Building Auditorium, HS610 155 College Street University of Toronto. International bilateral cooperation between Italy and Canada in scientific research and technology innovation is one of the priorities of Italy’s foreign policy, in order to ensure, through Italian know‐how, the country’s competitive abilities and the development of advanced production industries. The goal of this meeting of experts is to highlight Canada’s excellent capabilities in nutrition, as well as Italian areas of excellence in nutrition, food packaging, genomics, traceability, and the history of nutrition. Another aim is to increase awareness of the Canadian and Italian scientific communities, with a view to promoting innovation development at the international level and further enhancing bilateral cooperation between Italian and Canadian research centres and universities in a European context.
Pubblicato da fidest su mercoledì, 27 marzo 2013
London, PRNewswire Acne treatment has been in the headlines in recent months as studies have been conducted into the causes of the condition and the therapies used to tackle it. The team at The Laser Treatment Clinic in London has read the recent developments in this key area of dermatology with interest and has some advice for sufferers. A recent report in the Daily Mail suggested that a long-term study of the relationship between diet and acne found that high fat and high sugar diets were indeed related to the condition. This has inevitably led dermatologists and skin experts like those at The Laser Treatment Clinic to suggest that lifestyle changes represent a positive form of acne management. Taking more exercise and eating a healthy, balanced diet that does not rely too heavily on fat and sugar are considered the most positive changes to make. However, another report regarding the treatment of acne has also surfaced this month. Dianette is one of the drugs used to tackle persistent and troublesome cases of acne, but as this report, also from the Daily Mail, indicates, the medication is now banned in several countries in Europe. Dianette has been linked to the deaths of a number of British women but the drug is still prescribed for severe skin complaints in the UK. The team at The Laser Treatment Clinic is keen to point out that there is an alternative to intensive drug therapy when it comes to the treatment of active acne vulgaris and the scars left behind by the condition. Laser acne treatment and acne scar treatment are gaining popularity as successful and non-invasive means of diminishing breakouts of acne and reversing the damage historical breakouts do to the complexion. These forms of treatment are available at The Laser Treatment Clinic and the clinic currently has a promotion in place offering considerable discounts on forms of laser therapy. The Laser Treatment Clinic is based in Harley Street in London. The clinic was one of the very first advanced laser skin clinics to be founded in the capital and the team boasts over 13 years of experience in a wide range of treatment areas, including hair removal and scar treatment.
Pubblicato da fidest su mercoledì, 26 settembre 2012
London Frost & Sullivan’s “New Mega Trends” identifies and evaluates emerging Mega Trends and their sub trends, translating these to real opportunities for everyday business and personal life. This analysis – tested with Fortune 1000 companies – has now been developed into a book, “New Mega Trends,” which will launch this week.
Frost & Sullivan’s “New Mega Trends” identifies the 10 most important global New Mega Trends – sustained and macroeconomic forces of development that influence global businesses, economies, societies, cultures and our personal lives – that will redefine the future world.“New Mega Trends” includes:Connectivity and Convergence – With more than 80 billion connected devices, 9 billion mobile phones, 5 billion Internet users, five connected devices for every individual, 10 connected devices for every household, and 500 devices with unique digital IDs per square kilometre, consumers will pave the way to a digital planet by 2020. Connectivity will see wide-spread convergence of technologies, products and even industries.Health, Wellness and Wellbeing – Sustainability was one of the major trends of the last decade. Health, wellness and wellbeing will be the most important factor of discussion and differentiation in this decade. Healthcare spending will consume more than 15 percent of GDP by the middle of this decade (20 percent to 30 percent by 2050) and government’s inability to make the necessary investments will lead to a paradigm shift in the concept of healthcare.Smart is the new Green – The failure of green technology to show a manageable and predictable ROI will lead to a shift towards intelligent products that ‘behave’ green by adapting and changing to the environment around them through use of intelligent sensing and communication technology. The future will see use of several Smart products in our daily life, ranging from Smart (home) hubs connecting and integrating electronic/electrical equipment in our houses, Smart appliances that switch on and off themselves and Smart cloths that react to our body temperature or interact with mobile phones. This trend will lead to convergence of competition, with IT players, mobile operators, and energy companies competing to be the first to provide advanced smart solutions.In addition, the “New Mega Trends” addresses the “Macro to Micro” methodology, which can be applied to help identify “blue ocean,” or uncontested white space market opportunities, and also answer questions like:
How will we travel to work in the cities of the future?
What is Zero Vision, and is it the next big thing?
How will we stay connected in the future?
Will our wellness and wellbeing top the business agenda, and be more important than sustainability and the environment?
What new business models will succeed in future?
If you are a leader with a corporate vision, a strategic planner within your organization, or just curious about your future, Frost & Sullivan’s book, “New Mega Trends,” provides stimulating stories, startling facts and thought provoking case studies that will not only give a glimpse of how your future will be, but also reveals what opportunities lay in the here and now.“New Mega Trends,” written by Frost & Sullivan Partner Sarwant Singh and published by Palgrave Macmillan, will be launched Friday, 28th Sept. in the UK, Europe and Asia, and in the USA on Tuesday, 30th Oct.
Pubblicato da fidest su martedì, 22 maggio 2012
Bradford, England, (PRNewswire) A leading nutritional expert has called for more to be done by influential figures within the UK health and fitness industry after branding worrying obesity and diabetes levels as “freight trains running out of control”. Dr John Berardi, who was recently in the UK attending the FitPro convention, is a prominent researcher in the field of exercise and nutritional science and he believes a greater emphasis needs to be placed on engaging with and educating people of all ages on the benefits of eating healthy and exercising on a regular basis. Nearly a third of all children in the UK are now believed to be classified as overweight and just over a quarter of adults in England were classified as obese in 2010, highlighting how a major cultural problem is escalating. Speaking in an exclusive interview with Predator Nutrition founder Reggie Johal, Dr Berardi said: “While the health and fitness industry in the UK always impresses me, as a health and fitness culture, the UK is doing just about as poorly as we are in North America. “Personally, I split my time between the US and Canada, living part of the year in each country. And whether it’s the US, Canada, or the UK, we’re all struggling. Obesity and diabetes seem like freight trains running out of control. “Of course, that’s not a fitness industry thing. Instead, it has everything to do with the combination of sedentary labor, few natural opportunities for exercise and movement, huge access to high calorie, processed foods, and a tremendous amount of personal stress. “Just telling people to eat less and exercise more doesn’t work. Sure, it theoretically could work. But it can be damn hard for some people to get moving in this direction.”And the problem isn’t necessarily willpower. I know that’s hard to understand at first. But once you have a family to take care of, become a full-time member of a sedentary work force, and become responsible for meeting the needs of either young children or aging parents – and you have to do it all on a limited budget – does it become apparent why this is so hard for people.”That’s why I’m so passionate about reaching people where they’re at. Honestly, the obesity epidemic isn’t going to be solved by the fitness industry unless we reimagine what it is we do. Because, right now, the industry is confined to the four walls of gyms and health clubs.”It’s only when we’re willing reach out beyond fitness club walls and engage people at home, in their workplaces, and in the other places they spend time, that we’ll really have the impact we hope to.” Predator Nutrition is a prominent UK sports nutrition retailer. Follow them on Twitter and Facebook, and circle them on Google+ to receive news of the latest offers and money-saving deals.
Pubblicato da fidest su sabato, 19 maggio 2012
Qatar 23 May 2012, from 12:30-14:00 Salle IX, Palais des Nations Hosted by the Supreme Council of Health, The WHA technical session will share some of the achievements in patient safety since WHA Resolution 55.18 passed exactly 10 years ago in 2002, and serve as a renewed call to action to promote patient safety as a fundamental principle of all health systems. The session will focus on the successes and lessons learned from the implementation of global and national patient safety programmes in the past decade, and distil the key features of success that can be applied to strengthen health systems for quality improvements and safety. The session will also present a call to action coming from the recent Salzburg Global Seminar on Safety and Quality and look at new ways of moving forward to strengthen existing national efforts, while intensifying further global patient safety actions and the development of interventions.
ResearchMoz: Telemedicine Monitoring Market Shares, Strategies, and Forecasts, Worldwide, 2012 to 2018
Pubblicato da fidest su venerdì, 4 maggio 2012
Albany, New York, (PRNewswire) New Report Added in ResearchMoz Reports Database Telemedicine Monitoring Market Shares, Strategies, and Forecasts, Worldwide, 2012 to 2018 The 2012 study has 590 pages, 206 tables and figures. Worldwide markets are poised to achieve significant growth as the telemedicine systems provide a way to improve clinical care delivery to patients with chronic disease, decreasing hospitalizations and visits to the emergency room. To Browse Full TOC, Tables & Figures visit: http://www.researchmoz.com/telemedicine-monitoring-market-shares-strategies-and-forecasts-worldwide-2012-to-2018-report.html Chronic disease conditions are best treated early on when there is a change in patient condition and an early intervention can make a difference. It is even better to treat them in a wellness treatment environment before there are indications of chronic disease, before symptoms develop, by addressing lifestyle issues early on. Left to their own judgments, some patients typically are apt to make terrible decisions relating to their personal health either because of ignorance, genetic inheritance, or because of lifestyle habit. The ability to accurately access patient condition via a combination of advanced testing and telemonitoring creates the opportunity to intervene when what is called for clinically can make a difference, and permits provision for education regarding healthy living in a way that is likely to create compliance with clinician recommendations. Home telemonitoring programs need to use advanced technology. Effective monitors support patient education. They support timely clinician intervention based on real vital signs data gathered on a daily basis. Health care for patients with congestive heart failure has been shown to be successful in reducing hospitalizations and trips to the emergency department, making these critical measures unnecessary in many cases.
Pubblicato da fidest su mercoledì, 2 maggio 2012
Woodcliff Lake New Jersey, (PRNewswire)The Research Institute for Fragrance Materials, Inc. (RIFM) now has available, from its web site at http://www.rifm.org, human health safety assessments on Macrocyclic and Cinnamyl Phenyl Propyl fragrance Ingredients. Found in the Publications section of the RIFM site, Toxicologic and Dermatologic Assessments for Three Groups of Fragrance Ingredients: 1) Macrocyclic Ketones, 2) Macrocyclic Lactones and Lactides, 3) Cinnamyl Phenyl Propyl was published in Food and Chemical Toxicology, Vol 49, Suppl 2S, Dec 2011 and is already one of the journal’s top ten downloaded publications. Included in the review of the three groups are 24 related Fragrance Material Reviews (FMRs). Printed copies can be ordered from the RIFM Online Store.
These fragrance ingredients are used in many different product types, including cosmetic, personal care, household and air care. Based on all the data available, RIFM’s human health safety assessment shows that, at the current levels of use, these materials are practically nonirritating, have a low sensitization potential, no genotoxicity potential and a low order of repeat dose toxicity. The materials were already reviewed by RIFM for environmental impact and showed no grounds for environmental concern.
The opinion of the independent Expert Panel that reviews RIFM’s research is that, under the anticipated levels of exposure in fine fragrance and consumer products, there are no safety concerns regarding use of these materials.
RIFM is the international scientific authority for the safe use of fragrance materials. RIFM generates, evaluates and distributes scientific data on the safety assessment of fragrance raw materials found in personal and household care products. Through extensive research, testing and constant monitoring of all scientific literature available, RIFM maintains its Database as the most comprehensive source worldwide of physical-chemical, toxicological and eco-toxicological data associated with known fragrance and flavor materials. All of RIFM’s scientific findings are evaluated by an independent Expert Panel—an international group of dermatologists, pathologists, toxicologists, reproduction, respiratory and environmental scientists. The Expert Panel evaluates the safety of fragrance ingredients under conditions of intended use and publishes their results in peer-reviewed scientific journals. The decisions of the Expert Panel regarding restrictions of use are also published in the IFRA Standards. For more information about RIFM and its activities, visit http://www.rifm.org
Pubblicato da fidest su mercoledì, 11 aprile 2012
WHO’s Patient Safety Programme is proud to announce the release, last week, of the results of the first multi-country study on hospital adverse events, conducted in the Eastern Mediterranean and African Regions of WHO. These data show that patient safety concerns are as important in these regions as had been previously recognized in more economically developed ones. Results from the Eastern Mediterranean/African Adverse Events Study reveals that patients are suffering preventable permanent disability or dying due to unsafe health care in developing and transitional countries. On average, health-care related harmful incidents affected 8 in every 100 patients studied. These are conservative estimates that probably only reveal the tip of the iceberg, but that nevertheless highlight the importance and urgency of addressing patient safety globally.Experts found that an average of 8.2% of patients suffered what they term an “adverse event”. These were defined as unintended injuries that resulted in permanent disability or death that came about as a result of health-care management. In some hospitals, the situation was much worse, with almost one in five patients being affected by accidents and poor care. The researchers say that adverse events happen in the developed world too, but they point out that the chance of dying from an adverse event in a developing world hospital is much higher.
With 26 hospitals participating in the research, spread across Egypt, Jordan, Kenya, Morocco, Tunisia, Sudan, South Africa and Yemen, and in collaboration with the respective ministries of health and the two WHO Regional Offices, this study, which started back in 2005, has been one of the largest ones undertaken by the Patient Safety Programme.WHO would like to thank the participating hospitals who agreed to participate in this important and valuable patient safety study, acknowledging their courage and determination to help improve the situation in their own hospitals and further afield. Recognition is also due to the scientific teams in the eight participating countries, led by Prof. Ross Wilson. This study will now contribute towards placing patient safety strongly on the health policy agenda of developing and transitional countries. The EMRO-AFRO Adverse Event Study will shortly be published in the British Medical Journal (BMJ 2012;344:e832).The article can be read via this link to BMJ’s website http://www.bmj.com/content/344/bmj.e832, and you can also find below a link to our website where you can read the policy booklet prepared by PSP, as well as a media piece from the BBC: http://www.who.int/ patientsafety/ research/evidence_ of_unsafe/en/index.html, http://www.bbc.co.uk/news/health-17359796.
Pubblicato da fidest su lunedì, 19 marzo 2012
Uno studio retrospettivo di coorte, su pazienti anziani, ha riscontrato che la somministrazione di analgesici oppioidi dopo interventi di chirurgia ambulatoriale, si manteneva a lungo nel tempo. Lo studio, pubblicato su Archives of internal medicine, ha riscontrato che i pazienti che avevano ricevuto la prescrizione entro sette giorni dall’intervento avevano il 44% di probabilità in più di assumerli ancora dopo un anno, rispetto a coloro ai quali non erano stati prescritti. Inoltre, molti pazienti che avevano inizialmente ricevuto oppioidi più deboli, come la codeina, era poi passati ad agenti più potenti, e l’uso dell’ossicodone passava dal 5,4% nella prima settimana postoperatoria al 15,9% dopo un anno. Lo stesso andamento nelle prescrizioni è stato notato anche in chi era stato trattato con farmaci antinfiammatori non steroidei prescritti entro i sette giorni con un rischio relativo, rispetto a pazienti naive, di 3,74. Arch Intern Med.2012;172(5):425-430 (fonte fasrmacista33)
Pubblicato da fidest su mercoledì, 14 marzo 2012
Philadelfia and London, (PRNewswire) The Intellectual Property & Science business of Thomson Reuters announced today it was selected by Alzheimer’s Research UK, the Institute of Physics, the National Institutes of Health (NIH), and the National Science Foundation (NSF) to provide essential data and insight into ground-breaking scientific initiatives led by these organizations. These partnerships will shed new light on the current scientific environments in multiple fields, inform research, and influence policy decision making. Thomson Reuters was selected to provide citation data, unify disparate information sources, and apply insight based on its unique capabilities in evaluating, selecting, and analyzing scientific and scholarly data. For a current look at the state of the UK’s research in Alzheimer’s disease and physics, Thomson Reuters performed in-depth bibliometric evaluations to measure and compare performance and provide snapshots of where the UK stands in each field. These analyses were used in Alzheimer’s Research UK’s Defeating Dementia report and the Institute of Physics’ Bibliometric evaluation and international benchmarking of the UK’s physics research report, where objective Thomson Reuters data is helping to influence government policies and contribute to wider discussions of research in these fields. Thomson Reuters expertise also helps move research forward. Global Health Connect, a unique online resource for tackling the explosion of Big Data for global health, is under development in partnership with the National Institutes of Health’s Office of Technology Transfer and BIO Ventures for Global Health. Once complete, Global Health Connect will support the development of treatments for neglected diseases. These recent initiatives are backed by the history of trusted data Thomson Reuters has collected and curated. For forty years, the National Science Foundation has relied on Thomson Reuters citation data to produce its Science and Engineering Indicators, a volume of records comprising the major high-quality, quantitative data on the U.S. and international science and engineering enterprise. Independently-analyzed Thomson Reuters data is also the basis for the report’s Academic Research & Development chapter, one of the document’s seven major components.
Thomson Reuters is the world’s leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial, legal, tax and accounting, healthcare and science and media markets, powered by the world’s most trusted news organization. With headquarters in New York and major operations in London and Eagan, Minnesota, Thomson Reuters employs more than 55,000 people and operates in over 100 countries. Thomson Reuters shares are listed on the Toronto and New York Stock Exchanges. For more information, go to http://www.thomsonreuters.com.
Pubblicato da fidest su venerdì, 9 marzo 2012
Freiburg and Heidelgerg, Germany, (PRNewswire) Dr. Falk Pharma GmbH and Lipid Therapeutics, a biotechnology company focused on novel treatments for inflammatory bowel disease, today announced that they have entered into a licensing agreement for the European rights to Lipid Therapeutics’ lead product, LT-02, for ulcerative colitis (UC). The terms of the license include an upfront fee, milestones and royalties. Following a co-development and option-agreement in 2009, Dr. Falk GmbH will assume full responsibility for the further development and commercialization of LT-02 in Europe, with a Phase III induction trial in UC planned to start in the second half of 2012. Lipid Therapeutics is currently in discussions with potential development partners in the US. LT-02 is a delayed release formulation of phosphatidylcholine designed to improve the barrier function of the mucosal layer of the colon. Data from a positive European Phase II trial conducted in 156 patients with UC will be presented at the Digestive Disease Week (DDW) conference in San Diego on 22 May 2012. Ursula Falk, CEO of Dr. Falk Pharma, said: “We are pleased to exercise our option to license European rights to LT-02 based on the positive outcome of the recent Phase II trial. The novel mechanism of action, combined with an excellent safety profile, provides a new approach to treating UC patients who are poorly controlled on existing therapies.”
Dr. Gerhard Keilhauer, CEO of Lipid Therapeutics, added: “Our agreement with Dr. Falk Pharma is an important step towards bringing LT-02 to patients suffering from UC. We highly value Dr. Falk’s expertise in the gastrointestinal market. Lipid Therapeutics is now preparing to meet with the FDA to agree on a coordinated development pathway in the US and EU.” Prof. Dr. Wolfgang Stremmel, Director Dept. Gastroenterology, University Hospital Heidelberg, commented: “I am extremely excited that our research on the contribution of a deficit in mucosal phosphatidylcholine to the pathogenesis of ulcerative colitis has led to the development of a novel treatment option which is now going into pivotal clinical trials.
Ulcerative colitis is a chronic, relapsing inflammatory disorder that affects the mucosal lining of the large intestine. Clinical characteristics include rectal bleeding, diarrhea and abdominal pain. Worldwide more than 1 million people suffer from ulcerative colitis.
LT-02 is a novel delayed release formulation of phosphatidylcholine that augments the natural protective mucosal barrier in the lower gut. It is the first product candidate worldwide that targets the pathological changes in the barrier function of ulcerative colitis patients which are thought to be one of the main causes of underlying disease.
Lipid Therapeutics is a biopharmaceutical company focused on the development and commercialization of phospholipids and their use for the treatment of ulcerative colitis. Lipid Therapeutics was founded in 2008 by the EMBL Technology Fund to commercialize groundbreaking scientific work by Prof. Wolfgang Stremmel, Krehl University Clinic in Heidelberg. The company is headquartered in Heidelberg (Germany) and is financed through the EMBL Technology Fund and CD Ventures.
Dr. Falk Pharma GmbH is one of the most recognized companies worldwide in gastroenterology. Dr. Falk Pharma GmbH products are sold in more than 60 countries. The Falk Foundation, which is associated with the company, provides medical information via international symposia, forums, postgraduate courses and literature services. Over the past 45 years the Falk Foundation has sponsored more than 200 international Falk symposia and workshops in which over 100,000 researchers and physicians from 110 countries have come together to advance knowledge in gastroenterology and hepatology.
Pubblicato da fidest su venerdì, 9 marzo 2012
Geneva – A new book “The evolving threat of antimicrobial resistance – Options for action”, was launched today by the World Health Organization. It showcases examples of actions taken to slow down drug resistance and preserve the ability of medicines to effectively treat many infectious diseases. The steps taken by governments, health facilities and providers and others are examples of what had been recommended in the 2001 WHO Global Strategy for Containment of Antimicrobial Resistance.The book examines the experiences with implementing some of those recommendations ten years on, the lessons learnt along the way and the gaps still remaining. It draws attention to areas where knowledge is lacking and where urgent action is still needed.The aim of the book is to raise awareness about antimicrobial resistance (AMR) and stimulate further efforts to meet the recommendations outlined in the 2001 strategy and the 2011 World Health Day policy package. It does so by examining the current situation, and setting out what has been done and what more could be done around the world, in high-, middle- and low-income countries.While much of what is summarized in this publication is well known to the scientific community, awareness at the political level is essential, but often lacking. A specific objective is therefore to encourage policy decision-makers and the global community to commit to intensified action against AMR.
Over several decades, powerful medicines have been developed to treat diseases such as tuberculosis, malaria, HIV, influenza and many bacterial infections. All the medicines used to treat these infections will eventually become ineffective due to the development of resistance. AMR has evolved to become a worldwide health threat. Of critical importance is the fact that every antibiotic ever developed is at risk. This makes it difficult and more expensive to treat many common infections, causing delays in effective treatment or, in worst cases, an inability to provide effective treatment at all.”In terms of new replacement antibiotics, the pipeline is virtually dry. But much can be done,” says Dr Margaret Chan, Director-General of the World Health Organization. “This includes prescribing antibiotics appropriately and only when needed, following treatment correctly, restricting the use of antibiotics in food production to therapeutic purposes and tackling the problem of substandard and counterfeit medicines.”Drug resistance causes increased and prolonged illness, a greater risk of complications and higher death rates. Infections which are increasingly resistant to antibiotics are causing a heavy disease burden, particularly in developing countries.Some of the examples of a number of successful strategies and measures highlighted in the book include:
• In Thailand, the “Antibiotic Smart Use” programme reduces the prescribing of and demand for antibiotics by both prescribers and patients. It showed an 18%–46% reduction in antibiotic use while 97% of targeted patients recovered or improved regardless of whether they had taken antibiotics.
• A programme in pharmacies in Viet Nam consisting of inspection for prescription-only drugs; education on pharmacy treatment guidelines; and group meetings of pharmacy staff have resulted in a significant reduction in antibiotic dispensing for acute respiratory infections.
• In Norway, the introduction of effective vaccines in farmed salmon and trout together with improved fish health management reduced the annual use of antimicrobials in farmed fish by 98% between 1987 and 2004.
• In 2010, the University of Zambia School of Medicine revised their undergraduate medical curriculum. The topics of AMR and rational use of medicines were prominently inserted. The aim is that graduates enter clinical practice with the right skills and attitudes to be both effective practitioners
and committed stewards of AMR containment.
More information on the book, a link to download it and details on how to order a copy can be found on WHO Patient Safety’s web page: http://www.who.int/patientsafety/en/.
Pubblicato da fidest su giovedì, 16 febbraio 2012
Leiden Netherlands (PRNewswire) Aeon Astron Europe B.V., has been awarded a governmental grant up to EURO 500,000 from AgentschapNL, Dept. of Economic Affairs of the Netherlands for its Biolens projects to begin development of a multipurpose collagen-based ophthalmic lens for use in refractive correction, corneal repair and drug carrier. The AgentschapNL program is an initiative of the Dept. of Economic Affairs of the Netherlands to encourage development of bold and unconventional global health solutions. Aeon Astron Europe B.V. was encouraged to propose a breakthrough development for the production of a unique multipurpose ophthalmic lens, which is made from naturally occurring collagen into a transparent and biocompatible form of a contact lens that can easily be placed on the surface of the eye. The future of this collagen-based Biolens is highly promising. The unique feature of providing corneal protection, refractive correction, drug delivery and the potential for better and faster wound healing may eventually make this Biolens a standard part of ophthalmic practice.
Aeon Astron Europe B.V. is a privately held international biotech company based in the Netherlands. At Aeon Astron, we are dedicated to discovering, developing, producing and marketing of state-of-art regenerative solutions to save lives and restore health. We serve the medical community around the world to help medical professionals advance the standard of care to meet unmet medical needs for patients. As a global provider of regenerative solutions, our product pipeline expands across the fields of ophthalmology, dentistry, orthopedic and general and plastic surgery, including Biocornea, Biolens, Biobone, long-lasting dermal filler and 2-in-1 dental plug membrane among others.http://www.aeonastron.com/aeon01.php